vs

Side-by-side financial comparison of NOODLES & Co (NDLS) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $122.1M, roughly 1.2× NOODLES & Co). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -7.5%, a 2.0% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -4.1%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-2.8M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -1.2%).

Noodles & Company is an American fast-casual restaurant that offers international and American noodle dishes in addition to soups and salads. Noodles & Company was founded in 1995 by Aaron Kennedy and is headquartered in Broomfield, Colorado. The company went public in 2013 and recorded a $457 million revenue in 2017. In mid-2022, there were 458 Noodles & Company locations across 31 states.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

NDLS vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.2× larger
TARS
$151.7M
$122.1M
NDLS
Growing faster (revenue YoY)
TARS
TARS
+132.5% gap
TARS
128.4%
-4.1%
NDLS
Higher net margin
TARS
TARS
2.0% more per $
TARS
-5.5%
-7.5%
NDLS
More free cash flow
TARS
TARS
$15.8M more FCF
TARS
$13.0M
$-2.8M
NDLS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-1.2%
NDLS

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
NDLS
NDLS
TARS
TARS
Revenue
$122.1M
$151.7M
Net Profit
$-9.2M
$-8.4M
Gross Margin
Operating Margin
-5.2%
-5.3%
Net Margin
-7.5%
-5.5%
Revenue YoY
-4.1%
128.4%
Net Profit YoY
32.8%
63.8%
EPS (diluted)
$-0.20
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NDLS
NDLS
TARS
TARS
Q4 25
$151.7M
Q3 25
$122.1M
$118.7M
Q2 25
$123.8M
$102.7M
Q1 25
$78.3M
Q4 24
$122.8M
$66.4M
Q3 24
$127.4M
$48.1M
Q2 24
$121.4M
$40.8M
Q1 24
$124.3M
$27.6M
Net Profit
NDLS
NDLS
TARS
TARS
Q4 25
$-8.4M
Q3 25
$-9.2M
$-12.6M
Q2 25
$-9.1M
$-20.3M
Q1 25
$-25.1M
Q4 24
$-6.8M
$-23.1M
Q3 24
$-13.6M
$-23.4M
Q2 24
$-6.1M
$-33.3M
Q1 24
$-6.1M
$-35.7M
Operating Margin
NDLS
NDLS
TARS
TARS
Q4 25
-5.3%
Q3 25
-5.2%
-12.2%
Q2 25
-5.2%
-21.6%
Q1 25
-33.5%
Q4 24
-3.9%
-36.8%
Q3 24
-9.0%
-52.3%
Q2 24
-3.4%
-81.6%
Q1 24
-3.7%
-136.5%
Net Margin
NDLS
NDLS
TARS
TARS
Q4 25
-5.5%
Q3 25
-7.5%
-10.6%
Q2 25
-7.3%
-19.8%
Q1 25
-32.1%
Q4 24
-5.5%
-34.8%
Q3 24
-10.7%
-48.7%
Q2 24
-5.1%
-81.6%
Q1 24
-4.9%
-129.4%
EPS (diluted)
NDLS
NDLS
TARS
TARS
Q4 25
$-0.17
Q3 25
$-0.20
$-0.30
Q2 25
$-0.20
$-0.48
Q1 25
$-0.64
Q4 24
$-0.15
$-0.57
Q3 24
$-0.30
$-0.61
Q2 24
$-0.14
$-0.88
Q1 24
$-1.64
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NDLS
NDLS
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$4.7M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$-38.9M
$343.4M
Total Assets
$280.6M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NDLS
NDLS
TARS
TARS
Q4 25
$417.3M
Q3 25
$4.7M
$401.8M
Q2 25
$1.4M
$381.1M
Q1 25
$407.9M
Q4 24
$3.3M
$291.4M
Q3 24
$1.8M
$317.0M
Q2 24
$1.3M
$323.6M
Q1 24
$3.0M
$298.5M
Total Debt
NDLS
NDLS
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
NDLS
NDLS
TARS
TARS
Q4 25
$343.4M
Q3 25
$-38.9M
$335.1M
Q2 25
$-13.9M
$332.6M
Q1 25
$342.5M
Q4 24
$3.7M
$224.5M
Q3 24
$9.6M
$237.5M
Q2 24
$21.9M
$252.2M
Q1 24
$27.2M
$275.2M
Total Assets
NDLS
NDLS
TARS
TARS
Q4 25
$562.2M
Q3 25
$280.6M
$534.6M
Q2 25
$319.4M
$495.0M
Q1 25
$500.8M
Q4 24
$340.5M
$377.0M
Q3 24
$346.3M
$376.3M
Q2 24
$360.4M
$376.8M
Q1 24
$368.1M
$349.3M
Debt / Equity
NDLS
NDLS
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NDLS
NDLS
TARS
TARS
Operating Cash FlowLast quarter
$4.3M
$19.3M
Free Cash FlowOCF − Capex
$-2.8M
$13.0M
FCF MarginFCF / Revenue
-2.3%
8.6%
Capex IntensityCapex / Revenue
5.8%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.5M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NDLS
NDLS
TARS
TARS
Q4 25
$19.3M
Q3 25
$4.3M
$18.3M
Q2 25
$4.0M
$-29.4M
Q1 25
$-20.7M
Q4 24
$5.8M
$-22.2M
Q3 24
$4.7M
$-8.7M
Q2 24
$7.0M
$-14.4M
Q1 24
$164.0K
$-37.8M
Free Cash Flow
NDLS
NDLS
TARS
TARS
Q4 25
$13.0M
Q3 25
$-2.8M
$16.3M
Q2 25
$1.1M
$-30.4M
Q1 25
$-21.2M
Q4 24
$-1.3M
$-22.3M
Q3 24
$-4.5M
$-8.9M
Q2 24
$-1.6M
$-15.4M
Q1 24
$-15.2M
$-38.0M
FCF Margin
NDLS
NDLS
TARS
TARS
Q4 25
8.6%
Q3 25
-2.3%
13.8%
Q2 25
0.9%
-29.6%
Q1 25
-27.1%
Q4 24
-1.1%
-33.5%
Q3 24
-3.5%
-18.6%
Q2 24
-1.4%
-37.8%
Q1 24
-12.2%
-137.5%
Capex Intensity
NDLS
NDLS
TARS
TARS
Q4 25
4.2%
Q3 25
5.8%
1.6%
Q2 25
2.4%
1.0%
Q1 25
0.8%
Q4 24
5.8%
0.1%
Q3 24
7.2%
0.6%
Q2 24
7.1%
2.5%
Q1 24
12.3%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NDLS
NDLS

Food And Beverage$119.6M98%
Franchise$2.5M2%

TARS
TARS

Segment breakdown not available.

Related Comparisons